Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer
Quick Facts
- Publication title: Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer
- Journal: Sci Rep
- Year: 2026
- DOI: 10.1038/s41598-026-43719-x
- PMID/PMCID: 41826614; PMC13111588
Research overview
This study aimed to evaluate the therapeutic efficacy and immunomodulatory mechanism of exosome-delivered miR-1290 inhibitor in a PCa mouse model. These findings support miRNA-1290 as a promising therapeutic target and highlight exosome-based RNA therapeutics as a novel strategy for prostate cancer management, warranting further translational development.
Key findings
Prostate cancer (PCa) is a leading malignancy in men, particularly challenging in its advanced stages due to treatment resistance and immune evasion.
MicroRNA-1290 (miR-1290) was identified to be implicated in tumor progression, but its role in PCa remains insufficiently characterized.
Recent advances in exosome-based delivery systems provide opportunities to target oncogenic miRNAs in vivo.
This study aimed to evaluate the therapeutic efficacy and immunomodulatory mechanism of exosome-delivered miR-1290 inhibitor in a PCa mouse model.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Cell-Culture Supernatant EV Isolation & Purification, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Exosome-mediated delivery of miRNA-1290 inhibitor enhances JNK-dependent tissue-resident memory T cell immunity in prostate cancer Scientific reports. 2026. DOI: 10.1038/s41598-026-43719-x. PMID/PMCID: 41826614; PMC13111588.